Business Wire

Mars Petcare Marks Strategic Entry into European Veterinary Care Sector as Anicura to Join the Business

Jaa

Mars Petcare today announced that it has signed definitive agreements to acquire AniCura from Nordic Capital, Fidelio Capital and the remaining minority shareholders of AniCura. On completion of the transaction, AniCura will join the family of Mars Petcare’s veterinary health business units and will continue to pursue the expansion of its brand and high quality standards of medicine in Europe.

AniCura was founded in 2011 as the first merger of animal hospitals in the Nordic region. Since then, it has grown to become a role model for high-quality, specialized veterinary care for companion animals. AniCura now has more than 4,000 veterinary professionals, and 200 animal hospitals in seven countries across Europe. Its vision is to provide a first-class customer experience for pet owners and referring veterinarians alike.

The acquisition of AniCura represents Mars Petcare’s strategic entry into the European veterinary care sector. It brings together Mars Petcare’s notable veterinary expertise with AniCura’s well-established European business. This follows the announcement earlier in June 2018 that Linnaeus – a high-quality provider of veterinary care based in the UK – will also join Mars Petcare and will become a unit within Mars Petcare’s Veterinary Health Group.

Mars Petcare has been providing veterinary care since 1994 when it first began partnering with BANFIELD™ Pet Hospital. Today, it employs approximately 50,000 veterinary professionals and cares for more than 10 million pets annually. AniCura will join the family of Mars Petcare’s veterinary businesses alongside VCA™, BANFIELD™ Pet Hospital, BLUEPEARL™, PET PARTNERS™ and Linnaeus. Mars Petcare’s purpose is to create A BETTER WORLD FOR PETS and it is building upon and leveraging capabilities across its pet businesses to bring this to life. This includes food & nutrition, research, technology, and veterinary expertise – from wellness and prevention, through all aspects of veterinary care.

“Mars Petcare has a long and global history of providing nutrition, veterinary care and science for pets across the globe. Our veterinary business until now has been in the United States and Canada. Europe is the second largest region in the world for pet care, and European pet care is expected to grow significantly over the coming years. There is a great opportunity to address growing demand by providing high quality, consistent veterinary care across Europe”, said Poul Weihrauch, President, Mars Petcare. “Together, Mars Petcare and AniCura will both be in a position to benefit from each other’s best practices and competencies, improving clinical practice and continuing to advance the veterinary profession in both North America and Europe. This will support us in our purpose to create A BETTER WORLD FOR PETS.”

AniCura is well renowned for practicing quality medicine across its 200 animal hospitals and for the two million pets it cares for every year. It has well-regarded specialist care focus and a highly-qualified team, employing a high share of Diplomates from the European College across Sweden, Norway, Denmark, Germany, Austria, Switzerland and The Netherlands.

“Over the past years, with support from Nordic Capital and the additional owners, AniCura has grown to become a leading European provider of high-quality veterinary care, well-known for its focus on people, customer care and quality. The company is now ready to take the next step in its development”, said Peter Dahlberg, Chief Executive Officer, AniCura. “It was clear from early on that Mars Petcare shared our values of providing high-quality veterinary care and a first-class customer experience, and we are pleased to have found a long-term owner for AniCura to further improve the quality of European veterinary care”.

Completion of the transaction is subject to customary regulatory approvals. It is expected that the transaction will close in Q4 2018.

On completion of the deal, AniCura’s existing management will continue to lead the business. As part of the Mars Petcare family, AniCura will continue with the expansion of its brand and high quality standards of medicine in Europe. Financial terms of the transaction were not disclosed.

J.P. Morgan Securities plc acted as financial adviser and Freshfields Bruckhaus Deringer LLP and Cederquist acted as legal counsel to Mars.

About Mars Petcare

Mars Petcare is a diverse and growing business with 75,000 Associates across 50+ countries dedicated to one purpose: A BETTER WORLD FOR PETS. With 75 years of experience, our portfolio of almost 50 brands serves the health and nutrition needs of the world’s pets – including brands PEDIGREE ®, WHISKAS ®, ROYAL CANIN®, NUTRO™, GREENIES™, SHEBA ®, CESAR ®, IAMS™ and EUKANUBA™ as well as The WALTHAM Centre for Pet Nutrition which has advanced research in the nutrition and health of pets for over 50 years. Mars Petcare is also a leading veterinary health provider through a network of over 2,000 pet hospitals including BANFIELD™, BLUEPEARL™, PET PARTNERS™, and VCA™. We’re also active in innovation and technology for pets, with WISDOM PANEL™ genetic health screening and DNA testing for dogs, the WHISTLE™ GPS dog tracker, and LEAP VENTURE STUDIO accelerator and COMPANION FUND™ programs that drive innovation and disruption in the pet care industry. As a family business and guided by our principles, we are privileged with the flexibility to fight for what we believe in – and we choose to fight for: A BETTER WORLD FOR PETS.

About AniCura

AniCura is a family of well-known animal hospitals and clinics specialised in veterinary care for companion animals. Born out of the idea that sharing resources creates opportunities for better veterinary care, the company was established in 2011 by Fidelio Capital and The Animal Foundation in Greater Stockholm as the first merger of companion animal hospitals in the Nordic region. Today, AniCura is a role model within specialised veterinary care and a valued partner for pet owners and referring veterinarians across Europe. AniCura offers a wide range of high quality medical services covering preventive and basic health care as well as advanced diagnostics, internal medicine, intensive care, surgery and orthopaedics. AniCura also provides rehabilitation, physiotherapy and dietary advice and offers selected pet food and care products. AniCura provides modern, high-quality veterinary care for pets at 200 European locations and creates peace of mind for pet owners through excellent access and patient safety. Every year, AniCura’s 4,000 passionate veterinary professionals attend to more than two million companion animal patients. AniCura is a trusted training and referral body. For information on how AniCura is working to shape the future of veterinary care, please visit our website www.anicuragroup.com.

About Nordic Capital

Nordic Capital is a leading private equity investor in the Nordic region with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a proven track record. Core sectors are Healthcare, Technology & Payments, Financial Services, Industrial Goods & Services and Consumer & Retail, and key regions are the Nordics, Northern Europe, and globally for Healthcare. Since inception in 1989, Nordic Capital has invested EUR 12 billion in 100 investments. The Nordic Capital Funds are based in Jersey and are advised by advisory entities, which are based in Sweden, Denmark, Finland, Norway, Germany and the UK. For further information about Nordic Capital, please visit www.nordiccapital.com.

###

Contact information

CNC for Mars Petcare
Maximilian Karpf
maximilian.karpf@cnc-communications.com
or
Matthew Thomlinson
matthew.thomlinson@cnc-communications.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

PMI Launches Search for Next President and CEO22.10.2018 17:00Tiedote

Project Management Institute (PMI), the world’s leading professional membership organization for project managers, announced today that it has retained Heidrick & Struggles to help the organization find its next President and Chief Executive Officer (CEO). The dynamic leader shall oversee the implementation of a new strategic plan and guide the organization toward a future designed to help thousands of project professionals around the world accelerate their careers and make ideas a reality. Heidrick & Struggles is a premier provider of executive search, leadership assessment and development, organization and team effectiveness, and culture shaping services globally. PMI will conduct a comprehensive global review of both internal and external candidates for this key position. The selected candidate will embody PMI’s core values and possess the skillsets necessary to advance the organization’s key goals. PMI’s next President and CEO will help it execute a bold new multi-year initiative d

E2open to Acquire INTTRA, Adding the World’s Leading Ocean Shipping Network and Software Provider, Creating an Integrated Global Supply Chain and Logistics Operating Network22.10.2018 16:43Tiedote

E2open, the one place in the cloud to run your supply chain, today announced the acquisition of INTTRA, the leading ocean shipping network, software and information provider. The combination of INTTRA’s ocean carrier and shipper network with E2open’s industry leading business network will create a unified global logistics and supply chain network. E2open and INTTRA will join efforts to strengthen the connections and streamline the information flow between manufacturers, suppliers, shipping service providers, ocean carriers and all the participants in global trade. E2open is the largest cloud-based provider of networked supply chain solutions, featuring a complete portfolio of applications that enable the world’s most complex supply chains to better plan, collaborate, and execute their end-to-end operations. More than 70,000 partner companies and 200,000 users, many of the biggest brands and manufacturers across a range of industries, use the E2open network and platform to orchestrate t

Patient-Data Platform Raremark Raises £3m to Enable Precision Medicine in Rare Disease22.10.2018 15:00Tiedote

Raremark, the leading patient-data platform in rare disease, has raised £3m in funding from investors, led by AlbionVC and Ananda Ventures, with participation from Oltre Venture and from existing major investor the Cass Entrepreneurship Fund. The funding will be used to develop Raremark’s patient-engagement and data-analysis technology, helping biopharmaceutical companies to identify, engage and learn from patients, accelerating the development of new treatments. Raremark’s platform is the foundation for building research networks of rare disease patients and their families. Raremark provides biopharmaceutical companies with access to anonymized and aggregated patient data, helping to reduce the time and cost of clinical development. The Raremark platform engages and retains patients, leveraging machine-learning technologies in novel ways. The approach is designed to raise health literacy and informed participation in medical research, to improve the quality of existing therapies and t

Celltrion Healthcare Hosts Forum with Patient Advocacy Groups to Provide Information on the Use of Biosimilars in Oncology22.10.2018 14:50Tiedote

To coincide with the ESMO 2018 Congress in Munich, Germany, Celltrion Healthcare invited perspective from experts including a physician and pharmacist to provide information to patient advocacy groups on the history of biosimilars, how they are tested and approved, their cost saving benefit and the wealth of clinical evidence already available on their use in order to improve understanding of biosimilars. The introduction of biosimilars in the treatment of cancer has the potential to reduce pressure on healthcare budgets and increase access to other innovative treatments or more potent regimens. This is achieved by offering more cost-effective alternatives to the reference medicinal products and by increasing competition in the market. Breast cancer is the most common cancer in women worldwide and accounts for a quarter of all cancer diagnoses in women.1 For the benefits of biosimilar use to be realised in oncology, and in the treatment of breast cancer, barriers to their uptake need t

Sony Corporation Selects ANAQUA for IP Management22.10.2018 14:00Tiedote

Anaqua, Inc., the leading provider of innovation and intellectual property (IP) management solutions, today announced that multinational technology company Sony Corporation has entered into a multi-year agreement to use the ANAQUA software to manage its patent and trademark portfolios. Sony is one of the world’s largest technology and entertainment companies, with products spanning consumer electronics, smart phones, game and network services, financial services, and professional products. “We are excited to welcome one of the world’s largest companies and IP leaders to Anaqua’s growing client community,” said Bob Romeo, CEO of Anaqua. “Sony’s decision to strategically partner with Anaqua for their IP Management system reinforces our continued investment in the APAC market.” ABOUT ANAQUA The most innovative companies in the world innovate with Anaqua. Its simplified software platform combines insight from big data analytics with critical tools, best practice workflows and advanced serv

Dentsu Aegis Network Announces the Acquisition of Namics AG22.10.2018 14:00Tiedote

Dentsu Aegis Network today announces that it has signed a definitive agreement to acquire Namics AG, a leading full-service digital agency in Switzerland and Germany. Following the acquisition, which is subject to approval from the German competition authority, the company will become ‘Namics - A Merkle Company’. Namics’ digital experience, creative and service design expertise complements Merkle’s already significant customer experience (CX) and marketing technology practice in the region. An important step in Merkle’s strategy to increase its global footprint, it provides further scale and depth to Merkle’s people-based marketing capabilities, in particular in the areas of business transformation strategy, digital consulting and technology implementation across Adobe Experience Cloud, Sitecore, Salesforce and SAP and other leading technology partners. All Namics‘ 550 digital specialists based in Frankfurt, Hamburg, Munich, St. Gallen, Zurich and Belgrade will join Merkle, bringing it

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme